Clinical Proteomics

Non-canonical HLA-presented peptides are promising therapeutic targets, but their low abundance makes them difficult to reproducibly identify and quantify, particularly in multiplexed immunopeptidomics workflows. Here we present MIRA-MS (Model-Informed Real-time Acquisition for Mass Spectrometry), a real-time acquisition strategy that combines fragment ion-indexed database searching with artificial intelligence-based prediction of peptide fragmentation and retention time to guide quantitative scan acquisition. In a clear cell renal cell carcinoma model, MIRA-MS increased the number of quantified non-canonical immunopeptides by 97-107% relative to standard acquisition methods while also improving recovery of canonical peptides by 45-89%. These results establish real-time AI-guided acquisition as a powerful approach for deeper and more reproducible immunopeptidome profiling.

Data-dependent acquisition mass spectrometry (DDA-MS) and data-independent acquisition mass spectrometry (DIA-MS) have historically offered complementary strengths in bottom-up proteomics, with DDA providing high-selectivity spectra for post-translational modification (PTM) analysis and DIA enabling more systematic peptide sampling. Here, we asked if this is still the case for the Orbitrap Astral platform that offers high-speed DDA and (ultra-) narrow-window DIA (nDIA) capabilities across proteome and phosphoproteome applications. When DDA and DIA measurements were parameter-matched (to the extent possible), the differences in analytical performance diminished markedly. Across extensive replicate analyses, both methods continued to identify new peptides and proteins without reaching saturation, indicating that the molecular complexity of biological samples still overwhelms even the fastest liquid chromatography-MS (LC-MS) methods. Incomplete sampling also contributed to substantial peptide-level non-overlap between DDA and nDIA and data completeness was only modestly better for nDIA than DDA across many replicates. Quantitatively, DDA and nDIA showed broadly similar precision and accuracy, with nDIA offering slightly higher precision and DDA slightly better accuracy in controlled mixture experiments. MS1-based quantification outperformed MS2-based quantification, particularly for short gradients, supporting MS1 quantification as a robust and general strategy for high-throughput proteomics. In phosphoproteomic samples, DDA and nDIA identified similar numbers of phosphopeptides, but DDA retained a small edge for phosphorylation site localisation. Together, the results show that advances in acquisition speed and sensitivity are narrowing the historical gap between DDA and DIA, while also revealing that current LC-MS workflows remain far from providing comprehensive proteome coverage. Going forward, further gains in dynamic range, scan speed, sensitivity, and transparent software tools will be required to reach systematic, comprehensive and reliable measurements of complex proteomes in a single shot.

We compared traditional data-dependent acquisition mass spectrometry (DDA-MS) with the increasingly adopted data-independent acquisition (DIA-MS) to evaluate their relative utility for large-scale quantitative biofluid proteomics of lung compartments, specifically paired bronchoalveolar lavage (BAL) cells and bronchoalveolar lavage fluid (BALF). Using beryllium-related granulomatous lung disease as a focused model, we analyzed BALF and BAL cells from beryllium-sensitized (BeS) individuals using both acquisition strategies to assess proteome depth, quantitative completeness, and analytical robustness. In BAL cells, 5,640 proteins were identified by DDA-MS and 5,227 by DIA-MS; however, DIA-MS yielded markedly improved quantitative completeness, with 5,178 proteins ([~]99%) quantified across all samples compared with 3,539 ([~]63%) quantified by DDA-MS. While 3,397 proteins were quantified by both methods, DIA-MS uniquely quantified 1,781 lower-abundance proteins. Proteins identified by both DIA and DDA-MS approaches revealed pathways associated with granulomatous inflammation, including Toll-like receptor, clathrin-mediated endocytosis, sirtuin, and C-type lectin receptor signaling, whereas DIA-MS resolved additional pathways, such as the complement cascade, coagulation system, and JAK/IL-6-type cytokine signaling. In BALF, although more proteins were identified by DDA-MS than by DIA-MS (2,069 vs 1,742), DIA-MS achieved greater quantitative completeness, with 1,695 proteins quantified across all samples compared with 1,050 using DDA-MS, underscoring its suitability for biomarker-oriented analyses in lung fluid compartments. Together, these results support DIA-MS as a robust and sensitive platform for quantitative lung proteomics and discovery of disease-relevant protein signatures.

Data-independent acquisition (DIA) proteomics relies almost exclusively on beam-type collision-induced dissociation (HCD) because its short activation time supports fast acquisition rates required for DIA. However, HCD requires charge state calibration and is therefore imperfect for mixed-charge DIA isolation windows. Resonance-excitation collision-induced dissociation (reCID) offers a promising alternative to HCD for DIA because the ion activation is effectively independent of charge state. Historically, reCIDs longer activation time has been considered too slow for DIA. Here, we revisit reCID for DIA proteomics using a modified Orbitrap Tribrid Apex MultiOmics mass spectrometer (Apex) that recovers acquisition-matrix overhead as additional ion injection time, enabling reCID acquisition rates comparable to HCD. Using matched acquisition rate settings of tryptic HeLa digests, reCID achieved precursor and protein detections similar to HCD when used with Carafe fine-tuned, fragmentation-matched spectral libraries. Library fine-tuning improved reCID precursor detections more than HCD detections, 24% versus 5%, indicating that HCD-trained prediction models are suboptimal for reCID spectra. ReCID also maintained peptide-level quantitative performance, including ions measured per peptide, precision, and accuracy. Across seven NCI cancer cell lines and pooled mixtures, protein abundance rankings were highly conserved between the Apex reCID and HCD methods, and also across Orbitrap Astral Zoom platforms. These results support reCID as a practical fragmentation mode for DIA proteomics.

Plasma proteomics has long sought to accessibly sense human biology, precisely detect disease states, and advance diagnostics through clinical translation. In recent years, companies with defined panels such as Olink and Somascan have entered the field to complement bottom-up mass spectrometry (BUP). This study leverages a novel mass spectrometry platform to capture targeted proteoform information lost by mainline antibody-, aptamer-, and BUP-driven workflows. The Plasma Proteoform Assay (PPA) uses Individual Ion Mass Spectrometry (I{superscript 2}MS) to resolve mixtures of intact proteins presented by direct injection. Two proteoform panels, PPA 526 and PPA 1514, were defined from human plasma samples obtained from 81 individuals. The panels quantify 526 proteoforms derived from 59 genes and 1,514 proteoforms from 155 genes, respectively. Reproducibility for both panels showed coefficients of variation below 20% for most proteoforms (59-80%). PPA was benchmarked in studies including subjects with hepatic cirrhosis (N=30) and resilient agers carrying a SERPINE1 (PAI 1) mutation (N=27). PPA signatures distinguished SERPINE1 mutation carriers from affected individuals and provided sufficient resolution to discriminate among cirrhosis disease stages. In summary, we present PPA 526 and PPA 1514, the first scalable plasma proteoform panels capable of tracking hundreds to thousands of targets in a few minutes per sample.

Proteins are dynamically regulated by a myriad of post-translational modifications (PTMs) that control their stability, conformation, activity, subcellular localization, and local interactions. Capturing the precise composition of these various modification states, or proteoforms, is a principal objective of top-down proteomics (TDP). By ionizing intact proteoforms and combining measurements of precursor ion and fragment ion masses, the position, stoichiometry, and combination of PTMs can be determined. Despite the highly valuable measurements that TDP can provide, it is typically less sensitive than corresponding peptide-level analysis with many reports utilizing input material in the microgram to milligram range. Contributing to this lack of sensitivity is the risk of sample loss due to non-specific binding to surfaces during sample preparation. The most widely employed sample preparation approaches for TDP either require high sample input (e.g. precipitation and ultra-filtration) or fail to effectively remove surfactants (e.g. solid-phase extraction). These limitations have hindered advancement of targeted TDP applications involving immunoprecipitation and other enrichment strategies. Bead-assisted protein aggregation, also referred to as single-pot, solid-phase-enhanced sample preparation (SP3), has emerged as a popular sample preparation strategy for bottom-up proteomic workflows, but has only been used in TDP with secondary ion exchange chromatography cleanup. We envisioned a magnetic bead based protein cleanup approach that proceeds directly to MS analysis with judicious choice of bead surface chemistry and elution conditions. Here we report a sample preparation method using hydroxyl-functionalized magnetic beads for top-down proteomics applications.

Mass spectrometry-based single cell proteomics (SCP) is rapidly emerging as a powerful approach for biological research, with applications extending beyond in-vitro cancer cell lines. Recent advances make it possible to apply SCP to ex-vivo human cells from tissues such as the brain and pancreas, as well as to technically challenging immune populations such as neutrophils. However, these analyses remain more challenging and typically result in reduced proteomic coverage. To support the development of robust workflows for SCP data acquisition and analysis, we systematically evaluated multiple DIA search engines, search engine settings, the inclusion of high-load library samples in single-cell search spaces, the impact of contaminants, and the quantitative properties of identified proteins. These comparisons were performed across two major instrumentation platforms, Orbitrap Astral and timsTOF SCP, and across A549, RKO cells and neutrophils, three cell types differing in size and protein content. Our work here provides guidelines on the software parameters to use for SCP, instrument specific results and cell dependent optimizations of high-load libraries, as well as novel evaluation of the quantitative properties of proteins for single cell and low input proteomics.

AO_SCPLOWBSTRACTC_SCPLOWHigh-resolution mass spectrometry is routinely used for the analysis of complex samples in pharmaceutical, environmental, and omics related studies. Such applications require instrumentation to be capable of combining sub-ppm mass accuracy, high resolving power, rapid full m/z range acquisition, and a wide dynamic range. Achieving these requirements simultaneously places constraints on analyzer design and performance. Multi-reflecting time-of-flight (MRT) based analyzers have been previously reported as a means of extending effective flight path length in compact TOF designs. Here, further instrument and functionality advances in a compact MRT mass spectrometer design are described and the impact of these enhancements is demonstrated for omics applications.

Equitable access to large sample cohorts for robust, high-throughput proteomics for biomarker discovery is a major barrier to widescale clinical implementation. Dried blood spots (DBS) offer a minimally invasive alternative to venous blood draws, enabling at-home microsampling (<50 {micro}L) for centralised analysis, thus enhancing research participation. This approach is particularly relevant for under-represented groups, including children, the elderly, minority backgrounds and those with long-term health conditions such as chronic kidney disease (CKD), where disease fluctuations may occur outside the clinic, and vein preservation is critical. Proteomic analysis has demonstrated great utility in monitoring disease progression, and for biomarker/therapeutic target discovery. However, liquid chromatography-tandem mass spectrometry (LC-MS/MS) of whole blood is hindered by the wide dynamic range and the relatively high abundance of proteins such as haemoglobin, compromising biomarker discovery. Here, we establish an optimised workflow for protein extraction and haemoglobin depletion from microsamples obtained using DBS, enabling sensitive and high-throughput proteomic analysis. We demonstrate that haemoglobin depletion increases protein identifications by [~]50%, mitigating ion suppression and dynamic range effects, enabling the identification of putative biomarkers from patients with stage 5 CKD on dialysis. We also evaluated a commercial cell-free DBS device which yielded a sample more representative of plasma compared to traditional DBS and enabled greater depletion of haemoglobin compared to traditional DBS with haemoglobin depletion methods. Our findings offer a scalable approach for biomarker discovery, facilitating remote, longitudinal clinical studies.

N-glycolylneuraminic acid (Neu5Gc) has been repeatedly associated with human cancer, but reliable detection has remained elusive, generating controversy regarding its presence in human samples. To address this, matrix-matched calibration curves, which have been pioneered in proteomics and metabolomics for assessing changes in complex mixtures, were measured of released N-glycans at four orders of magnitude dynamic range in defined mixtures, systematically benchmarking Neu5Gc-containing N-glycan detection across multiple LC-MS platforms and sites. Orthogonally, the gold-standard analytical method, consisting of fluorescence detection of labelled monosaccharides separated by LC, was applied to the same samples, yielding absolute concentrations of Neu5Gc. LC-MS demonstrated an extended detection range of three or more orders of magnitude while retaining intact N-glycan measurement, improving assay specificity and enabling detection of the variety of Neu5Gc-bearing N-glycans. By combining orthogonal dimensions of evidence, including chromatographic separation, isotopic distribution matching, and composition-confirming MS/MS, LC-MS confidently resolved Neu5Gc signals from noise, even at low abundance. In comparison, DMB-LC-FLR was limited to two orders of magnitude dynamic range, insufficient for detection of Neu5Gc in commercially available pooled human sera. These findings strongly support that DMB-LC-FLR assay specificity and sensitivity are insufficient for Neu5Gc detection in human samples due to noise overwhelming the Neu5Gc signal. By establishing a reusable benchmarking framework for future glycomic studies, we aim to use LC-MS to improve the measurement of Neu5Gc in clinical samples.

The chorioallantoic membrane (CAM) model represents a promising three-dimensional in vivo platform for preclinical drug testing in human tissues. In this study, we investigated whether the tissue penetration and distribution of benzbromarone, a known inhibitor of the Ca2+ activated chloride channel TMEM16A and potential therapeutic agent for autosomal dominant polycystic kidney disease (ADPKD), can be successfully visualized in human renal cyst tissue cultured on the CAM. To this end, desorption electrospray ionization mass spectrometry imaging (DESI-MSI) combined with an ultrahigh-resolution time-of-flight mass spectrometer was employed. We achieved spatially resolved molecular mapping of endogenous metabolites and lipids as well as the applied compound. MSI enabled clear differentiation between CAM and cystic tissue based on their distinct lipid profiles. Benzbromarone was reproducibly detected in the cyst specimens and exhibited selective accumulation along the cyst epithelium, which is considered the principal site of action. These observations were complemented by multivariate analyses including Uniform Manifold Approximation and Projection (UMAP), and sparse multinomial logistic zero-sum classification. The data-driven approach confirmed molecular differences between tissue types and allowed accurate classification of drug-treated and untreated regions. This study demonstrates that topically applied benzbromarone penetrates human renal cyst tissue in the CAM model and localizes to pharmacologically relevant tissue regions, notably the location of the Ca2+ activated chloride channel TMEM16A in the epithelial lining. The integration of high-resolution DESI-MSI with advanced statistical analysis provides a robust and label-free method to study drug distribution in human tissue grafts. Our findings contribute to the advancement of translational research in analytical chemistry and pharmacology.

This protocol describes the workflow for the preparation of tissue samples for proteome and phosphoproteome analyses using mass spectrometry. The tissue samples are cryogenically pulverized and homogenized in a sucrose-based buffer to ensure proper tissue disruption. For depletion of lipid contaminants, proteins are purified using chloroform-methanol precipitation, followed by a resuspension in a urea-based buffer for enzymatic digestion. Peptides are desalted and enriched for phosphopeptides prior LC-MS/MS analysis. The workflow was developed for skin biopsies but is compatible with a broad range of tissue types. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=51 SRC="FIGDIR/small/732915v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@6a44aforg.highwire.dtl.DTLVardef@c34dc9org.highwire.dtl.DTLVardef@27d7ecorg.highwire.dtl.DTLVardef@1d1038e_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstractC_FLOATNO C_FIG

Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease of motor neurons for which therapeutics are limited. Improved biomarkers are imperative to improve patient care and therapeutic development. Here, we employed 35-plex isobaric tandem mass tag labeling based on isobutyl-proline reporter group (TMTpro) to perform unbiased proteomic analysis of cerebrospinal fluid (CSF) and plasma from control (n= 28, n= 31) and sporadic ALS (sALS) (n= 39, n= 41), from the Target ALS Global Natural History Study (TALS GNHS). We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform. This initial cross-sectional proteomic study of biofluids from the TALS GNHS, with unrestricted availability of study results to the research community, highlights the potential of this resource as a potent platform for ALS biomarker discovery.

Deep characterization of intact proteoforms remains an analytical challenge in functional proteomics, particularly for heterogenous multi-site post-translational modifications at distinct amino acid residues. Histones are among the most dynamically and diversely post-translationally modified proteins in eukaryote cells, carrying multiple, co-occurring and reversible modifications that can give rise to isomeric proteoform species. Tandem mass spectrometry with multimodal fragmentation capabilities is a promising approach for deep characterization of intact proteoforms, such as modified histones. We applied the novel timsOmni mass spectrometer, which incorporates the Omnitrap platform enabling multimodal MS workflows, for residue-level mapping of histone modifications, including acetylation and methylation. Recombinant histones H3.1 and H4 were in vitro acetylated by enzymes GCN5, PCAF and p300 to generate mono- and multi-acetylated proteoforms. Complementary MS2 electron- and collision-based dissociation (ECD, EID, RCID and ECciD), together with MS3 strategies, produced complete or near-complete backbone fragmentation of intact protein ions (>92% amino acid sequence coverage). For monoacetylated species generated by the more site-selective lysine acetyltransferases, the dominant proteoform matched the known catalytic preferences of the enzymes (H3.1K14ac for GCN5 and PCAF, and H4K8ac for PCAF), while minor positional isomers were also identified and their relative abundance estimated. In contrast, the broader substrate specificity of p300 produced a wide distribution of H4 proteoforms bearing up to seven acetylated lysine residues. Species carrying six and seven acetylations were characterized by multimodal MS2/MS3 experiments, enabling localization of individual acetylation sites and discrimination of positional isomers. Finally, endogenous histone proteoforms from liver extracts were analyzed, yielding sequence coverages of 92-93% for the most abundant species and enabling confident localization of multiple PTMs (acetylation and methylation). These results illustrate that multimodal MSn fragmentation of intact proteins supports residue-level assignment of combinatorial histone marks and coexisting positional isomers. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=165 HEIGHT=200 SRC="FIGDIR/small/722147v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@387ab5org.highwire.dtl.DTLVardef@2410org.highwire.dtl.DTLVardef@13fc392org.highwire.dtl.DTLVardef@140e054_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIMultimodal MS{superscript 2}/MS3 maps histone PTMs on intact proteins. C_LIO_LIECD, EID, RCID, and ECciD provide complete or near-complete sequence coverage. C_LIO_LIMS3 localizes acetylation sites, distinguishes positional isomers. C_LIO_LIEndogenous H4 proteoforms are assigned with site-specific PTM mapping. C_LI

High-throughput data-independent acquisition (DIA) workflows paired with short chromatographic separations are increasingly adopted for systems biology and clinical proteomics. However, narrower peak widths from rapid separations demand faster mass spectrometer cycle times to maintain quantitative depth and reproducibility. The synchro-PASEF acquisition mode on timsTOF mass spectrometers diagonally scans across ion mobility and m/z space, enabling efficient sampling of the precursor ion cloud with shortened cycle times. While synchro-PASEF has demonstrated competitive identification depth for global protein abundance samples compared to conventional dia-PASEF, its performance for phosphoproteomics - where the precursor ion cloud is characteristically broader and bimodally distributed - has not been evaluated. Here, we systematically optimized synchro-PASEF methods for phosphoproteomics and benchmarked performance against two dia-PASEF methods across three sub-hour separations. We found that synchro-PASEF performance depends critically on balancing diagonal window number, total isolation width, and gradient length, with longer gradients favoring more windows for selectivity and shorter gradients favoring fewer windows to preserve sampling frequency. An optimized configuration quantified over 19,000 localized phosphosites using a 23-minute separation. Retention time summation (RTsum) with a factor of 2 increased phosphopeptide identifications by 5-20% and reduced phosphosite-level coefficients of variation by up to 30% across all dia-PASEF and synchro-PASEF methods tested. Using {beta}2-adrenergic receptor (B2AR) activation as a signaling model, we demonstrate that label-free DIA phosphoproteomics can be used to model phosphoproteomics dose-response relationships, showing that synchro-PASEF and dia-PASEF produce highly concordant phosphoproteomic responses, with comparable numbers of responding phosphosites, similar effect sizes, and nearly identical predicted protein kinase A (PKA) substrates downstream of the activated B2AR. While synchro-PASEF did not surpass optimized dia-PASEF in identification depth, its comparable biological performance and amenability to post-acquisition optimization through RTsum support its utility for high-throughput phosphoproteomics. This work provides a transferable framework for synchro-PASEF method optimization and demonstrates the broad utility of retention time summation for PASEF-based phosphoproteomics workflows.

The extracellular matrix (ECM) and cell surface glycocalyx are key components of biology and play crucial roles in development and tissue function, as well as disease. Proteoglycans, and their glycosaminoglycan (GAG) side chains, are critical components of the ECM and the glycocalyx. GAGs can bind to many different proteins, such as chemokines, and form hydrated barriers around cells. Existing and new methods are helping us to uncover more about the roles of GAGs in biology. Here, we expand on existing technologies and provide streamlined, standardised and well-documented methods that can be easily adopted in standard analytical facilities. We provide extensive detailed step-by-step guides describing sample disruption, GAG disaccharide preparation from biological tissues and their analysis by HILIC-MS/MS. In addition, we demonstrate utility of this method when using a range of different samples as biological sources. This method will sit alongside existing and new techniques to help improve access to GAG analysis, and thereby further the field of understanding GAG function in complex biological contexts.

Lipid metabolism reflects the dynamic balance between metabolic turnover and concentration. Kinetic mass spectrometry (MS) enables direct quantification of molecular turnover in vivo. Previous work has shown that MS-based kinetic proteomics has provided powerful insights into proteome regulation. Analogous lipidome-wide kinetic measurements remain limited by challenges in defining molecule-specific labeling behavior. Here, we extend kinetic MS to untargeted lipidomics. Isotope labeling with deuterated water (2H2O) is commonly used for monitoring turnover of palmitate and other select lipids by measuring labeling of stable CH positions with deuterium (2H). Here, we extend the deuterium-incorporation model underlying these targeted lipid turnover assays to support untargeted analysis of all detectable lipids. This allows us to empirically quantify the effective fraction of endogenous synthesis (Asyn) and the turnover rate (k) across hundreds of lipid species simultaneously. One central barrier to lipidome-wide kinetic modeling is determining the endogenous number of deuterium-labeling sites for each molecule (nL) which is required to estimate Asyn and k accurately. The nL value is an essential component of biological kinetic assays. In kinetic proteomics, curated amino acid nL libraries enable peptide-level modeling by summing sequence-specific labeling-site values, but comparable resources are lacking for lipids and may not generalize across metabolic states or non-mammalian systems. Yet, gaps remain for lipids and for amino acids in modified metabolic conditions or non-mammalian biologies. Here, we empirically determine lipid nL values and validate the process with peptides against an nL library. To evaluate this strategy in a biologically relevant setting, we applied it to brain tissue from transgenic mice expressing human ApoE isoforms, where altered lipid transport and metabolism are implicated in Alzheimers disease risk. These data validate the method in a clinically relevant context and suggest that genotype-dependent metabolism can alter empirically determined lipid nL values.

Small extracellular vesicles (sEVs) are key mediators of intercellular communication, influencing diverse pathological processes, including cancer. While mass spectrometry (MS) has enabled the proteomic analysis of sEVs, sample preparation losses remain a critical bottleneck, particularly for scarce tissue-derived sEVs (Ti-EVs). Here, we systematically benchmark five proteomic workflows introducing Exo-insert, a novel single-vessel method, and Exo-SP3, across both Ti-Evs and cell culture-derived sEVs (CCM-EVs) at low input (0.5-4 {micro}g). Exo-insert and Exo-SP3 enable the identification of [~]1100 protein groups from as little as 0.5 {micro}g sEV input. Notably, optimal sample preparation for MS is source-dependent: Exo-insert and Exo-SP3 display divergent performance across sEV sources. Comparative DDA/DIA analyses establish sample preparation as the primary determinant of proteome recovery, offering a practical framework that matches workflows to sEV amounts and source-specific content for biomarker discovery.

Plasma proteomics is increasingly important for biomarker discovery and disease stratification; however, comprehensive and high-throughput analysis remains challenging because of the extreme dynamic range of plasma proteins. We previously established tomato lectin affinity purification-based mass spectrometry (TomAP-MS), a workflow that enhances plasma proteome coverage via tomato lectin-mediated enrichment. The initial workflow depended on a 4% sodium dodecyl sulfate (SDS) elution, followed by SP3-based purification and digestion, which raised complexity and restricted throughput. In this study, we developed an improved TomAP-MS workflow incorporating lauryl maltose neopentyl glycol (LMNG)-assisted acid elution (LAcE), in which proteins are eluted under acidic conditions in the presence of LMNG. This process is followed by pH adjustment and direct tryptic digestion without SP3 cleanup. Compared with conventional acid elution and the original SDS/SP3 workflow, LAcE increased protein identifications while simplifying sample preparation and improving throughput. Using the optimized workflow, we identified more than 7,500 proteins from human plasma and demonstrated broader applicability in extracellular vesicle enrichment and protein interaction analysis workflows. We demonstrated that ethylenediaminetetraacetic acid plasma was the preferred specimen type, enabling the identification of over 5,000 proteins from just 1 {micro}L of plasma, with minimal impact on proteomic profiles after up to three freeze-thaw cycles. Additionally, the analysis of plasma from 200 healthy individuals reproducibly detected 4,117 proteins across all samples, including many proteins associated with inherited disorders. These findings establish TomAP-MS with LAcE as a practical platform for deep plasma proteomics, supporting its future application in proteomics-based screening and diagnostics.

Metabolite detection with mass spectrometry (MS) in untargeted metabolomics is limited by the wide concentration range of metabolites, where high-abundance signals dominate MS1 scans and suppress detection of low-abundance features. This reduces metabolite coverage and obscures biologically relevant signals, particularly in complex cellular systems. Full Scan enhanced Dynamic Range (eDR) MS addresses these limitations by partitioning the MS1 mass range into multiple subscans and mass windows, reducing saturation effects from dominant ions. Here, we systematically evaluate different eDR acquisition strategies for untargeted metabolomics. Across four hepatocellular carcinoma cell lines, Full Scan eDR MS increased detectable features up to [~]3.5-fold compared to Full Scan MS. Among equidistant window configurations, 12 windows yielded the highest feature count and broadest dynamic range, while custom window distributions further improved detection in ion-dense regions. In particular, allocating smaller window sizes to the low m/z region selectively increased detection of low-mass features while preserving performance for higher mass ions. Full Scan eDR MS also improved data quality, reducing variation and increasing signal-to-noise ratios, especially for low-abundance metabolites. MS2 coverage and metabolite identifications increased substantially, resulting in unique detection of cancer-relevant metabolites. Importantly, the increased depth of metabolite detection enabled improved discrimination between cancer cell lines, supporting deeper interrogation of metabolic heterogeneity. Overall, these results establish Full Scan eDR MS as a flexible strategy to improve sensitivity and metabolome coverage in untargeted metabolomics. Customization of window size and distribution enable targeted expansion of dynamic range within predefined mass regions, allowing MS acquisition to be tailored to sample complexity and metabolites of interest.